Abstract

As there are no effective treatments for muscular dystrophy (MD), identifying systemically acting small-molecule therapeutics is desirable. Tyrosine phosphorylation of β-dystroglycan, which occurs via tyrosine kinase in dystrophin-deficient muscles, has been reported to induce muscle damage, and several tyrosine kinase inhibitors have been researched as potential therapeutic agents for MD. Nilotinib, a second-generation tyrosine kinase inhibitor, was potentially effective in MD by reducing muscle fibrosis. However, there was a problem that its direct effect on satellite cells inhibited muscle differentiation. Dasatinib, a third-generation tyrosine kinase inhibitor, is also expected to be effective in MD, but its effect on muscle regeneration is unknown.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call